Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product aids in lung function by reducing surface tension, facilitating breathing. Manufactured by Chiesi Farmaceutici S.P.A., it is essential for neonatal intensive care units.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the infant's lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers can improve lung compliance and oxygenation, making it easier for the infant to breathe. The therapy is crucial for supporting lung development in premature babies.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and prevent the collapse of alveoli. This action facilitates easier breathing and improves oxygen levels in the blood. The effects are typically observed soon after administration, providing immediate relief for infants suffering from respiratory distress.

Curosurf should be administered by trained healthcare professionals in a controlled medical environment. It is essential to follow proper handling and storage guidelines to maintain the product's efficacy. Patients with known allergies to any of the components should avoid using Curosurf. Always consult a healthcare provider for personalized advice.

Curosurf is generally used in a controlled medical setting, minimizing the risk of interactions with other medications. However, it is important to inform healthcare providers about any other treatments the infant is receiving. Always follow the guidance of a medical professional to ensure safe and effective use.